MiR-519d, whose levels was downregulated in the blood plasma of NSCLC patients, was discovered to limit the progression of the disease via inhibiting HER3 and deactivating the PI3K/Akt pathway (61). Here, PIK3CA is linked to non-small cell lung carcinoma.